vTv Therapeutics
vTv Therapeutics is a late-stage clinical biopharmaceutical company developing cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as the first potential oral adjunctive therapy to insulin for Type 1 diabetes.
- Company typePublic
- Founded2015
- HeadquartersHigh Point, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What vTv Therapeutics does
vTv Therapeutics is a late-stage clinical biopharmaceutical company headquartered in High Point, North Carolina, that develops oral small-molecule drug candidates for diabetes and related chronic diseases. The company's lead asset is cadisegliatin (TTP399), a liver-selective glucokinase activator (GKA) designed to restore the liver's natural role in glucose storage and release; it is being investigated as the first potential oral adjunctive therapy to insulin for people with Type 1 diabetes (T1D), a population of approximately 1.5 million Americans where roughly 75% do not maintain the American Diabetes Association's HbA1c target of less than 7%. Cadisegliatin received FDA Breakthrough Therapy designation in April 2021 and is currently enrolling the Phase 3 CATT1 trial, with enrollment targeted for Q3 2026 and topline data expected in the first half of 2027. Supporting pipeline assets include TTP273, an Nrf2/Bach1 modulator program, the PPAR-delta agonist HPP593 (Mavodelpar), and HPP737, a PDE4 inhibitor whose global rights were licensed to Newsoara Biopharma in February 2026 for $20 million upfront plus up to $115 million in milestones and tiered royalties.
vTv Therapeutics firmographics
Firmographics- Name
- vTv Therapeutics
- Legal name
- vTv Therapeutics Inc.
- Website
- https://vtvtherapeutics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- vTv Therapeutics is a late-stage clinical biopharmaceutical company developing cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as the first potential oral adjunctive therapy to insulin for Type 1 diabetes.
- Ownership category
- akta.pro rank
vTv Therapeutics industry classification
Industry- Product category
- Diabetes Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
Keywords
Where vTv Therapeutics is headquartered
LocationHeadquarters
- HQ city
- High Point
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
vTv Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales (Future): Revenue from commercializing cadisegliatin and other drug candidates upon regulatory approval. As a late-stage biopharmaceutical company, vTv's primary future revenue stream would be product sales of prescription pharmaceuticals distributed through pharmacy channels.
- Licensing and Milestone Payments: Revenue from licensing agreements including upfront payments, development milestones, and sales milestones. The company received $20 million upfront from Newsoara for HPP737 global rights, with potential additional milestones of up to $115 million. Previous licensing deals included $25 million from G42 Healthcare and $10 million from CinPax.
- Royalties on Net Sales: Ongoing royalty payments based on net sales of licensed products. The HPP737 license agreement includes tiered royalties on future sales.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
vTv Therapeutics product offering
Product offeringCore offering
vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator currently in a Phase 3 trial as a potential first-in-class adjunctive therapy to insulin for Type 1 diabetes. The company also develops HPP737 (a PDE4 inhibitor licensed to Newsoara), TTP273, an Nrf2/Bach1 program, and a PPAR-delta agonist.
Product overview
vTv Therapeutics is a late-stage biopharmaceutical company developing a portfolio of oral small-molecule drug candidates for diabetes and related chronic diseases. The company's clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as an adjunctive therapy to insulin for type 1 diabetes. Supporting candidates include TTP273, Nrf2/Bach1 Program, TTP-RA, and PPAR-δ (HPP593/MAVODELPAR). HPP737, a PDE4 inhibitor, has been licensed to Newsoara Biopharma for global development and commercialization. The company operates as a single-focus pharmaceutical developer rather than a platform-based product company.
Differentiator
Problem solved
Functional benefit
Products and services
- Cadisegliatin (TTP399) Oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of Type 1 diabetes; currently in the Phase 3 CATT1 trial with FDA Breakthrough Therapy designation and potential to become the first FDA-approved oral adjunctive therapy to insulin.
- HPP737 (PDE4 inhibitor)
Quantifiable outcome
- 0.3% statistically significant reduction in HbA1c (p=0.0017) in 12-week SimpliciT1 Phase 2 trial (n=81)
- +4 more outcomes
Companies that use vTv Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
vTv Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
vTv Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Newsoara Biopharma Co. Ltd.coreExpanded license agreement granting Newsoara Biopharma exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. vTv received a $20 million upfront payment in February 2026, with potential development milestones of up to $50 million, sales milestones of up to $65 million, and tiered royalties on net sales. The prior regional license agreement (May 2018) had become void in June 2025, and this amendment establishes a global collaboration.
- M42's Insights Research Organization & Solutions (IROS)coreCollaboration with M42's IROS to conduct a Phase 2 clinical trial evaluating cadisegliatin as adjunctive therapy to insulin for Type 2 diabetes. The trial will enroll approximately 300 patients across the UAE, Jordan, and Tunisia, with first patient visit expected in Q1 2026. Under the collaboration, vTv serves as regulatory sponsor while M42 funds the study.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
vTv Therapeutics competitors and assessment
Company assessmentDirect peers
- Zealand Pharma: Clinical-stage biopharmaceutical company developing peptide-based therapeutics for diabetes and metabolic diseases, sharing similar development-stage dynamics, public-company status, and therapeutic area focus.
- MannKind Corporation: Public biopharmaceutical company focused on diabetes therapeutics with commercialized inhaled insulin (Afrezza) and endocrine pipeline, directly comparable in therapeutic area and stage of commercialization.
- Provention Bio: Was a T1D-focused biopharmaceutical company developing teplizumab (Tzield) for Type 1 diabetes, acquired by Sanofi in 2023. Highly comparable in T1D focus and late-stage development prior to acquisition.
- Lexicon Pharmaceuticals: Late-stage clinical biopharmaceutical company developing small-molecule drug candidates for diabetes and other metabolic diseases, with comparable market cap profile and clinical-stage business model focused on oral therapies.
Broad incumbents
- Novo Nordisk: Global leader in insulin therapy (NovoLog, Levemir, Tresiba, Fiasp) and diabetes care, setting the standard of care that cadisegliatin would complement as adjunctive therapy if approved.
- Sanofi: Major diabetes player with established insulin portfolio (Lantus, Toujeo) and acquired Provention Bio's T1D asset teplizumab (Tzield), positioning the company as both broad incumbent and direct T1D competitor.
- Eli Lilly and Company: Major diabetes incumbent with leading insulin franchise (Humalog, Humulin, Lyumjev) and incretin therapies (Mounjaro, Trulicity), representing the dominant competitive backdrop and standard of care for any new T1D therapeutic.
Emerging players
- Insulet Corporation: Omnipod tubeless insulin pump and AID system provider, competing in T1D management through device innovation that could reduce demand for pharmacological adjuncts over time.
- Dexcom: Leading continuous glucose monitor manufacturer whose G6/G7 technology addresses T1D glycemic control and hypoglycemia without pharmacology, representing a non-pharmacological competitive approach in the same patient population.
- Tandem Diabetes Care: Insulin pump and automated insulin delivery system manufacturer (t:slim X2, Control-IQ) offering device-based solutions for T1D management, addressing the same patient population via alternative modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
vTv Therapeutics social profiles
Digital presencevTv Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
vTv Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
vTv Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
vTv Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
vTv Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about vTv Therapeutics
What does vTv Therapeutics do?
vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator currently in a Phase 3 trial as a potential first-in-class adjunctive therapy to insulin for Type 1 diabetes. The company also develops HPP737 (a PDE4 inhibitor licensed to Newsoara), TTP273, an Nrf2/Bach1 program, and a PPAR-delta agonist.
Is vTv Therapeutics a public or private company?
vTv Therapeutics is a public company. It is classified as public and is currently operating.
When was vTv Therapeutics founded?
vTv Therapeutics was founded in 2015. It employs 11 to 50 people.
Where is vTv Therapeutics based?
vTv Therapeutics is headquartered in High Point, United States, in the North America region.
How does vTv Therapeutics make money?
Three revenue lines are on record. Pharmaceutical Product Sales (Future) is the primary driver. The others are licensing and Milestone Payments and royalties on Net Sales.
Who are vTv Therapeutics's main competitors?
Direct peers on record are Zealand Pharma, MannKind Corporation, Provention Bio and Lexicon Pharmaceuticals. Broad incumbents are Novo Nordisk, Sanofi and Eli Lilly and Company. Emerging players are Insulet Corporation, Dexcom and Tandem Diabetes Care.
Does vTv Therapeutics have an API?
No public API is recorded for vTv Therapeutics.
What industry is vTv Therapeutics in?
vTv Therapeutics's product category is Diabetes Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.